124 related articles for article (PubMed ID: 9208874)
1. Biologic activities of natural and synthetic type I interferons.
Pfeffer LM
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-63-S9-69. PubMed ID: 9208874
[TBL] [Abstract][Full Text] [Related]
2. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Pfeffer LM; Dinarello CA; Herberman RB; Williams BR; Borden EC; Bordens R; Walter MR; Nagabhushan TL; Trotta PP; Pestka S
Cancer Res; 1998 Jun; 58(12):2489-99. PubMed ID: 9635566
[TBL] [Abstract][Full Text] [Related]
3. Domains of interaction between alpha interferon and its receptor components.
Uzé G; Di Marco S; Mouchel-Vielh E; Monneron D; Bandu MT; Horisberger MA; Dorques A; Lutfalla G; Mogensen KE
J Mol Biol; 1994 Oct; 243(2):245-57. PubMed ID: 7932753
[TBL] [Abstract][Full Text] [Related]
4. Functional significance of globotriaosyl ceramide in interferon-alpha(2)/type 1 interferon receptor-mediated antiviral activity.
Khine AA; Lingwood CA
J Cell Physiol; 2000 Jan; 182(1):97-108. PubMed ID: 10567921
[TBL] [Abstract][Full Text] [Related]
5. Effect of alpha-interferons on immune function.
Herberman RB
Semin Oncol; 1997 Jun; 24(3 Suppl 9):S9-78-S9-80. PubMed ID: 9208876
[TBL] [Abstract][Full Text] [Related]
6. Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
Brideau-Andersen AD; Huang X; Sun SC; Chen TT; Stark D; Sas IJ; Zadik L; Dawes GN; Guptill DR; McCord R; Govindarajan S; Roy A; Yang S; Gao J; Chen YH; Skartved NJ; Pedersen AK; Lin D; Locher CP; Rebbapragada I; Jensen AD; Bass SH; Nissen TL; Viswanathan S; Foster GR; Symons JA; Patten PA
Proc Natl Acad Sci U S A; 2007 May; 104(20):8269-74. PubMed ID: 17494769
[TBL] [Abstract][Full Text] [Related]
7. Type I interferon subtypes produced by human peripheral mononuclear cells from one normal donor stimulated by viral and non-viral inducing factors.
Palmer P; Tovey MG; Raschilas F; Brassart L; Meritet JF; Porcher R; Lebon P
Eur Cytokine Netw; 2007 Jun; 18(2):108-14. PubMed ID: 17594944
[TBL] [Abstract][Full Text] [Related]
8. Biological basis for a proper clinical application of alpha interferons.
Antonelli G
New Microbiol; 2008 Jul; 31(3):305-18. PubMed ID: 18843884
[TBL] [Abstract][Full Text] [Related]
9. Integrin alpha 11 is a novel type I interferon stimulated gene.
Leomil Coelho LF; Mota BE; Sales PC; Marques JT; de Oliveira JG; Bonjardim CA; Peregrino Ferreira PC; Kroon EG
Cytokine; 2006 Mar; 33(6):352-61. PubMed ID: 16697656
[TBL] [Abstract][Full Text] [Related]
10. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2.
Piehler J; Schreiber G
J Mol Biol; 1999 Nov; 294(1):223-37. PubMed ID: 10556041
[TBL] [Abstract][Full Text] [Related]
11. A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities.
Ozes ON; Reiter Z; Klein S; Blatt LM; Taylor MW
J Interferon Res; 1992 Feb; 12(1):55-9. PubMed ID: 1573283
[TBL] [Abstract][Full Text] [Related]
12. [Receptor system of interferons].
Yonehara S
Gan To Kagaku Ryoho; 1984 Jan; 11(1):44-52. PubMed ID: 6320747
[TBL] [Abstract][Full Text] [Related]
13. Differential expression and activity of the porcine type I interferon family.
Sang Y; Rowland RR; Hesse RA; Blecha F
Physiol Genomics; 2010 Jul; 42(2):248-58. PubMed ID: 20406849
[TBL] [Abstract][Full Text] [Related]
14. Detection of functional interferon alpha receptors in human neuroendocrine tumor cell lines using a new monoclonal antibody.
Rosolen A; Colamonici OR; Pfeffer LM; Whitesell L; Nordan R; Neckers LM
Eur Cytokine Netw; 1992; 3(2):81-8. PubMed ID: 1316782
[TBL] [Abstract][Full Text] [Related]
15. Creation of interferon-alpha8 mutants with amino acid substitutions against interferon-alpha receptor-2 binding sites using phage display system and evaluation of their biologic properties.
Yamamoto K; Taniai M; Torigoe K; Yamamoto S; Arai N; Suemoto Y; Yoshida K; Okura T; Mori T; Fujioka N; Tanimoto T; Miyata M; Ariyasu H; Ushio C; Fujii M; Ariyasu T; Ikeda M; Ohta T; Kurimoto M; Fukuda S
J Interferon Cytokine Res; 2009 Mar; 29(3):161-70. PubMed ID: 19196068
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.
Buckwold VE; Wei J; Huang Z; Huang C; Nalca A; Wells J; Russell J; Collins B; Ptak R; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
Antiviral Res; 2007 Feb; 73(2):118-25. PubMed ID: 16987555
[TBL] [Abstract][Full Text] [Related]
17. Identification of residues of the IFNAR1 chain of the type I human interferon receptor critical for ligand binding and biological activity.
Cajean-Feroldi C; Nosal F; Nardeux PC; Gallet X; Guymarho J; Baychelier F; Sempé P; Tovey MG; Escary JL; Eid P
Biochemistry; 2004 Oct; 43(39):12498-512. PubMed ID: 15449939
[TBL] [Abstract][Full Text] [Related]
18. Multichain structure of the IFN-alpha receptor on hematopoietic cells.
Colamonici OR; Pfeffer LM; D'Alessandro F; Platanias LC; Gregory SA; Rosolen A; Nordan R; Cruciani RA; Diaz MO
J Immunol; 1992 Apr; 148(7):2126-32. PubMed ID: 1531999
[TBL] [Abstract][Full Text] [Related]
19. Variations in the unstructured C-terminal tail of interferons contribute to differential receptor binding and biological activity.
Slutzki M; Jaitin DA; Yehezkel TB; Schreiber G
J Mol Biol; 2006 Jul; 360(5):1019-30. PubMed ID: 16815442
[TBL] [Abstract][Full Text] [Related]
20. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation.
Russell-Harde D; Wagner TC; Perez HD; Croze E
Biochem Biophys Res Commun; 1999 Feb; 255(2):539-44. PubMed ID: 10049744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
